( It includes discussions on non-pharmac...)Annual Meeting of the Consortium of Multiple Sclerosis Centers,Focuses on the Challenges of Care and Research in Multiple,Sclerosis,Health

It includes discussions on non-pharmaceutical strategies and assessments, medication management, rehabilitation, and for some instances, intrathecal delivery of baclofen, a technology that has revolutionized rehabilitation in MS. Developed by a team on behalf of the CMSC, headed by Dr. Francois Bethoux, Danni Gogol, RN, and Matt Sutliff, physical therapist, it will be featured on the CMSC website after the launch. The development of this program was a CMSC project partially supported by Medtronic, Inc. 3. Numerous presentations throughout the week will focus on new and important information about MS research. A new feature of CMSC includes a "late breaking" poster session on June 1st in which Dr. Mark S. Freedman, Professor of Neurology at the University of Ottawa, will share results from a study that validates that immediate treatment of early stages of MS with an immunomodulatory agent can significantly slow the onset of disability.

Dr. Freedman is an investigator of the study called BENEFIT (BEtaseron in Newly Emerging multiple sclerosis For Initial Treatment) that tested whether earlier stages of MS can also benefit from pharmaceutical intervention. Results showed that prompt initiation of Betaseron treatment in patients with a first MS attack was associated with a 40 percent reduced risk of confirmed disability progression over three years. This study confirms that early treatment is desirable in MS to avoid or diminish long-term disability. Betaseron is approved for the treatment of relapsing forms of MS to reduce the frequency of clinical exacerbations. Patients with MS in whom efficacy has been demonstrated include patients who have experienced a first clinical episode and have MRI features consistent with MS.

For information about the Consortium of Multiple Sclerosis Centers,
'"/>

Page: 1 2 3
Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
4. Micromet, Inc. to Present at the 3rd Annual C.E. Unterberg, Towbin Emerging Growth Conference
5. Neurologix to Present at the Third Annual C.E. Unterberg Towbin Emerging Growth Conference
6. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
7. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
8. MaxCyte and Medinet to Present at the 13th Annual Meeting of the International Society for Cellular Therapy (ISCT) in Sydney, Australia
9. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
10. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
11. Neurogen Proprietary Insomnia Compound Data for Two Studies Presented at Associated Professional Sleep Societies Annual Meeting